SK Biopharmaceuticals (CEO Jo Jung-woo) announced on the 19th that it will make a joint investment in ‘Cala Health’, an American electronic drug company, with SK, an investment company.
Starting with this investment, SK Biopharmaceuticals plans to continue strategic investments in high-tech pharmaceutical, bio, and healthcare companies.
Carla, an electronic drug company located in Silicon Valley, launched the world’s only ‘non-invasive electrical stimulation essential tremor’ treatment device in 2019. In addition, it has wearable platform technology that can be applied to the treatment of neurological and mental disorders and a sales network across the United States.
As a strategic investor (SI), SK Biopharmaceuticals is also exploring the possibility of technological cooperation in the field of color and brain science. Since 2018, SK Biopharmaceuticals has been conducting research and development of epilepsy seizure detection and prediction algorithms and devices, and is concurrently carrying out external collaboration and investment.
In particular, in the case of an epilepsy seizure detection device, domestic clinical trials are scheduled to begin this year, and it aims to present at the Consumer Electronics Show (CES) next year.
Renee Ryan, president of Carla Hell, said, “We are delighted that SK Biopharmaceuticals, a global pharmaceutical and biotech company, will participate in Carla’s investment. will,” he said.
SK Biopharmaceuticals CEO Jo Jung-woo said, “We will continue to secure innovative technologies by implementing various open innovations such as strategic investments in the future. We will be reborn as a solution company.”
/cloudfront-ap-northeast-1.images.arcpublishing.com/chosun/DFQL3KBMMETUN6HFI7UM6WWPFQ.jpg?fit=300%2C300&ssl=1)
